ArQule, Inc. (Nasdaq: ARQL) today announced that the following presentations of clinical data for tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase, and for ARQ 621, an inhibitor of the Eg5 kinesin motor protein, will take place at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 3-7, 2011 at McCormick Place, Chicago, Illinois.
